JP2024502990A5 - - Google Patents
Info
- Publication number
- JP2024502990A5 JP2024502990A5 JP2023541251A JP2023541251A JP2024502990A5 JP 2024502990 A5 JP2024502990 A5 JP 2024502990A5 JP 2023541251 A JP2023541251 A JP 2023541251A JP 2023541251 A JP2023541251 A JP 2023541251A JP 2024502990 A5 JP2024502990 A5 JP 2024502990A5
- Authority
- JP
- Japan
- Prior art keywords
- inventions described
- inventions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134336P | 2021-01-06 | 2021-01-06 | |
| US63/134,336 | 2021-01-06 | ||
| US202163170246P | 2021-04-02 | 2021-04-02 | |
| US63/170,246 | 2021-04-02 | ||
| PCT/US2022/011448 WO2022150483A1 (en) | 2021-01-06 | 2022-01-06 | Inhalable imatinib formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502990A JP2024502990A (ja) | 2024-01-24 |
| JP2024502990A5 true JP2024502990A5 (enExample) | 2025-01-15 |
Family
ID=82357645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541251A Pending JP2024502990A (ja) | 2021-01-06 | 2022-01-06 | 吸入可能なイマチニブ製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220241278A1 (enExample) |
| EP (1) | EP4274577A4 (enExample) |
| JP (1) | JP2024502990A (enExample) |
| AU (1) | AU2022205940A1 (enExample) |
| CA (1) | CA3204054A1 (enExample) |
| WO (1) | WO2022150483A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4311539A1 (en) * | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| PL2305263T3 (pl) * | 2007-06-07 | 2012-12-31 | Novartis Ag | Stabilizowane amorficzne formy mesylanu imatinibu |
| CN102008734A (zh) * | 2010-12-02 | 2011-04-13 | 深圳海王药业有限公司 | 一种α晶型伊马替尼的包合物及其制备方法 |
| JP6280546B2 (ja) * | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| EP3782604A1 (en) * | 2013-07-31 | 2021-02-24 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| US20200360477A1 (en) * | 2019-05-16 | 2020-11-19 | Aerovate Therapeutics, Inc. | Inhalable formulations for kinase inhibition |
-
2022
- 2022-01-06 CA CA3204054A patent/CA3204054A1/en active Pending
- 2022-01-06 EP EP22737106.9A patent/EP4274577A4/en active Pending
- 2022-01-06 WO PCT/US2022/011448 patent/WO2022150483A1/en not_active Ceased
- 2022-01-06 AU AU2022205940A patent/AU2022205940A1/en active Pending
- 2022-01-06 JP JP2023541251A patent/JP2024502990A/ja active Pending
- 2022-04-12 US US17/719,042 patent/US20220241278A1/en active Pending